CorMedix Management
Management criteria checks 4/4
CorMedix's CEO is Joe Todisco, appointed in May 2022, has a tenure of 3.75 years. total yearly compensation is $2.36M, comprised of 27.1% salary and 72.9% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $2.98M. The average tenure of the management team and the board of directors is 2 years and 3.9 years respectively.
Key information
Joe Todisco
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 27.09% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%
Feb 06
CorMedix Faces A Hard Reset As CMS Reimbursement Headwinds Emerge
Jan 09CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors
Dec 23Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position
Aug 14It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)
Aug 09Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Jun 27
DefenCath Launch Will Boost Inpatient And Dialysis Opportunities
Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships.The Hidden Risks Behind CorMedix's First Profitable Quarter
Mar 26Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jan 17CorMedix: Finally In Commercialization Mode
Jan 07CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark
Dec 13Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns
Nov 14Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Nov 04CorMedix 2.0: New Leadership, New Approval, New Focus
Oct 28CorMedix: Delayed Approval, Low Cash, Good Prospects
Oct 19We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Sep 30We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Apr 06We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Nov 02Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 31CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
Feb 25FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%
Aug 08Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$162m |
| Jun 30 2025 | n/a | n/a | US$51m |
| Mar 31 2025 | n/a | n/a | US$17m |
| Dec 31 2024 | US$2m | US$639k | -US$18m |
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$53m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$2m | US$617k | -US$46m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$3m | US$378k | -US$30m |
Compensation vs Market: Joe's total compensation ($USD2.36M) is about average for companies of similar size in the US market ($USD2.25M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Todisco (48 yo)
Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022 and is its Chairman of the Board of Directors from January, 2026. He is a Director of Talph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board of Directors | 3.8yrs | US$2.36m | 0.51% $ 3.0m | |
| Executive VP | 2yrs | US$1.14m | 0.082% $ 477.5k | |
| EVP & Chief Business Officer | less than a year | US$1.09m | 0.034% $ 201.1k | |
| EVP & Chief Financial Officer | less than a year | no data | 0.011% $ 62.7k | |
| EVP, Chief Legal and Compliance Officer & Corporate Secretary | 2.2yrs | no data | no data | |
| SVP & Chief Human Resource Officer | less than a year | no data | no data | |
| Senior VP & Head of Global Quality | 3.8yrs | no data | no data | |
| Senior VP & Head of Technical Operations | 3.1yrs | no data | no data | |
| EVP & Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: CRMD's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board of Directors | 3.9yrs | US$2.36m | 0.51% $ 3.0m | |
| Lead Independent Director | 9.8yrs | US$210.56k | 0.29% $ 1.7m | |
| Independent Director | 6.9yrs | US$153.56k | 0.051% $ 299.1k | |
| Independent Director | 10.5yrs | US$159.56k | 0.049% $ 285.9k | |
| Independent Director | 8.7yrs | US$174.56k | 0.12% $ 724.4k | |
| Independent Director | 5.3yrs | US$153.56k | 0.049% $ 284.8k | |
| Member of Scientific Advisor Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
Experienced Board: CRMD's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 07:06 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CorMedix Inc. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Butler | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |